Back to Journals » Therapeutics and Clinical Risk Management » Volume 4 » Issue 2

New approaches in the treatment of HIV/AIDS – focus on maraviroc and other CCR5 antagonists

Authors Schlecht HP, Schellhorn S, Dezube BJ, Jacobson JM

Published 11 April 2008 Volume 2008:4(2) Pages 473—485


Hans P Schlecht1, Sarah Schellhorn2, Bruce J Dezube3, Jeffrey M Jacobson1

1Department of Medicine (Infectious Diseases), Hahnemann University Hospital, Drexel University College of Medicine, Philadelphia, PA, USA; 2Department of Medicine, 3Department of Medicine (Hematology/Oncology), Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA

Abstract: Treatment of HIV-1 infection has produced dramatic success for many patients. Nevertheless, viral resistance continues to limit the efficacy of currently available agents in many patients. The CCR5 antagonists are a new class of antiretroviral agents that target a necessary coreceptor for viral entry of many strains of HIV-1. Recently, the first agent within this class, maraviroc, was approved by a number of regulatory agencies, including the Food and Drug Administration. Herein we review the role of the CCR5 receptor in HIV-1 infection and potential methods to target it in anti-HIV-1 therapy. We review the various categories of agents and discuss specific agents that have progressed to clinical study. We discuss in detail the recently approved, first in class CCR5 antagonist, maraviroc, and discuss aspects of resistance to CCR5 antagonism and the potential role of CCR5 antagonism in the management of HIV-1 infection.

Keywords: CCR5, HIV-1 tropism, coreceptor, maraviroc, viral entry, chemokine receptor

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]